查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球基因工程工具市場——行業規模、份額、趨勢、機會、2018-2028 年預測、按類型、按治療領域、按最終用戶、按地區、按競爭
市場調查報告書
商品編碼
1244130

全球基因工程工具市場——行業規模、份額、趨勢、機會、2018-2028 年預測、按類型、按治療領域、按最終用戶、按地區、按競爭

Genetic Engineering Tool Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2018-2028 Segmented By Type, By Therapeutic Area, By End User, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 116 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球基因工程工具市場預計在 2024-2028 年預測期內呈現強勁增長。

這可能是由於生物技術和遺傳學領域的進步。 基因組醫學和個性化醫學的日益普及將推動未來幾年全球基因工程工具市場的增長。 截至 2020 年，美國大約有 286 種個性化藥物可用。

醫藥行業的增長帶動市場增長

醫療保健行業正在全球範圍內迅速擴張，增加對醫療保健行業發展的資金正在為市場增長創造更多有利可圖的機會。 其中一個行業，即製藥行業，是最先進的，由於在其生產、設計和製造中廣泛使用基因工程工具，未來幾年將實現巨大增長。 精準醫學、基因組醫學和其他先進療法的快速增長將在未來五年進一步推動全球基因工程工具市場的增長。

基因工程在製藥行業的第一個成功產品是胰島素等蛋白質藥物。 用作生物反應器的微生物被用來增加蛋白質的量和大量生產藥物。 轉基因動植物也被用來生產各種微生物不能生產的蛋白質藥物。

研發和技術開發支持市場發展

基因工程是一個不斷發展的生物技術領域。 由於對基因編輯和基因組操作的長期和持續研究，預計未來幾年全球基因工程工具市場將出現強勁增長。 隨著慢性病的流行和對這些疾病治療方法的需求激增，全球基因工程工具市場將在預測期內出現增長。

微染色體技術或 RNA 轉錄修飾是主要的基因工程工具之一，有望得到進一步研究，從而支持未來幾年全球基因工程工具市場的增長。 CRISPR-Cas9 基因改造是一種有望幫助市場增長的基因療法。 此外，基因工程可以以多種方式應用。 基因工程工具在基因組修飾中的進一步應用是另一個有前途的研究領域，將在未來幾年推動全球基因工程工具市場的增長。

農業基因工程

在基因工程的幫助下，對農業部門進步的需求進一步證明了未來幾年全球基因工程工具市場的增長。 根據生物技術遊說團體 ISAAA 的數據，2018 年，轉基因作物種植面積為 1.917 億公頃，比 2017 年增長 1%。 美國擁有 7500 萬公頃土地（佔世界的 39%），是世界上最大的轉基因作物生產國。 提高作物產量，降低食品和藥品生產成本，減少對殺蟲劑的需求，強化營養素，提高食品質量，抵抗病蟲害，增加糧食安全，增加全球人口醫療效果等是與使用相關的主要優勢的基因工程工具。 基因工程工具參與農業生產更好的作物也將在未來幾年推動全球基因工程工具市場的增長。

市場細分

全球基因工程工具市場根據類型、治療領域、最終用戶和地區進行細分。 根據類型，市場進一步細分為基因組規模的編輯工具和基因組規模的工程工具。 根據治療領域，市場分為鐮狀細胞病、心髒病、糖尿病、阿爾茨海默病、肥胖症等。 基於最終用戶，市場再次細分為生物技術和製藥公司、學術研究機構等。 此外，市場分析將市場劃分為亞太、北美、歐洲、南美、中東和非洲，並設計了區域市場細分。

公司簡介

Thermo Fisher Scientific Inc、CRISPR Therapeutics AG、Editas Medicine, Inc、Intellia Therapeutics, Inc、Merck KGaA、Horizo□□n Discovery Ltd、GeneCopoeia Inc、Takara Bio Inc.、Sangamo Therapeutics, Inc、Genscript Biotech Corporation 等全球領先平台市場參與者引領基因工程工具市場的增長。

調查範圍：

本報告將全球基因工程工具市場分為以下幾類，行業趨勢詳述如下：

基因工程工具市場，按類型分類

  • 基因組規模的編輯工具
    • 基因編輯技術
    • 法師
    • 聲明
    • 創建
    • 其他
  • 基因組規模的工程工具
    • 啟動子工程
    • 核醣體結合位點 (RBS) 工程
    • 合成小分子調節 RNA
    • 其他
    • 基因工程工具市場，按治療領域劃分：
  • 鐮狀細胞病
  • 心髒病
  • 糖尿病
  • 阿爾茨海默氏癡呆症
  • 肥胖
  • 其他

最終用戶的基因工程工具市場：

  • 生物技術公司、製藥公司
  • 學術和研究機構等
  • 其他

按地區劃分的基因工程工具市場

  • 北美
    • 美國
    • 墨西哥
    • 加拿大
  • 歐洲
    • 法國
    • 德國
    • 英國
    • 意大利
    • 西班牙
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳大利亞
    • 泰國
    • 新加坡
  • 中東和非洲
    • 南非
    • 沙特阿拉伯
    • 阿聯酋
    • 以色列
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞

競爭格局

公司概況：對全球遺傳工具市場主要參與者的深入分析。

可自定義：

根據市場數據，TechSci Research 根據公司的具體需求提供定制服務。 該報告可以定制為：

公司信息

  • 對其他市場參與者（最多 5 家公司）進行深入分析和概況分析。

內容

第 1 章概述

  • 市場定義
  • 市場範圍
    • 目標市場
    • 研究目標年份
    • 主要市場細分

第二章研究方法論

  • 調查目的
  • 基線調查方法
  • 主要行業合作夥伴
  • 主要協會和次要信息
  • 調查方法
  • 數據三角測量和驗證
  • 假設和限制

第 3 章執行摘要

  • 市場概覽
  • 主要市場細分概述
  • 主要市場參與者概覽
  • 主要地區/國家概覽
  • 市場驅動因素、挑戰和趨勢概述

第 4 章 VOC（客戶之聲）

  • 常用的基因工程技術
  • 常用的基因編輯技術
  • 基因重組工具的應用優勢
  • 基因工程工具的優先級（按治療領域）
  • 阻礙基因重組工具傳播的事情
  • 品牌知名度

第五章基因工程工具的全球市場展望

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按類型（基因組規模編輯工具/基因組規模工程工具）
    • 按治療領域（鐮狀細胞病、心髒病、糖尿病、阿爾茨海默病、肥胖症等）
    • 最終用戶（生物技術/製藥公司、學術/研究機構等）
    • 按公司分類（2022 年）
    • 按地區
  • 市場地圖
    • 按類型
    • 按治療領域
    • 最終用戶
    • 按地區

第六章北美基因工程工具市場展望

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按類型（基因組規模編輯工具/基因組規模工程工具）
    • 按治療領域（鐮狀細胞病、心髒病、糖尿病、阿爾茨海默病、肥胖症等）
    • 最終用戶（生物技術/製藥公司、學術/研究機構等）
    • 按國家
  • 北美：國家/地區分析
    • 美國
    • 墨西哥
    • 加拿大

第七章歐洲遺傳工具市場展望

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按類型（基因組規模編輯工具/基因組規模工程工具）
    • 按治療領域（鐮狀細胞病、心髒病、糖尿病、阿爾茨海默病、肥胖症等）
    • 最終用戶（生物技術/製藥公司、學術/研究機構等）
    • 按國家
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 意大利
    • 西班牙

第八章亞太基因工程工具市場展望

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按類型（基因組規模編輯工具/基因組規模工程工具）
    • 按治療領域（鐮狀細胞病、心髒病、糖尿病、阿爾茨海默病、肥胖症等）
    • 最終用戶（生物技術/製藥公司、學術/研究機構等）
    • 按國家
  • 亞太地區：國家/地區分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳大利亞
    • 泰國
    • 新加坡

第9章南美遺傳工具市場展望

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按類型（基因組規模編輯工具/基因組規模工程工具）
    • 按治療領域（鐮狀細胞病、心髒病、糖尿病、阿爾茨海默病、肥胖症等）
    • 最終用戶（生物技術/製藥公司、學術/研究機構等）
    • 按國家
  • 南美洲：：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲基因工程工具的市場前景

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按類型（基因組規模編輯工具/基因組規模工程工具）
    • 按治療領域（鐮狀細胞病、心髒病、糖尿病、阿爾茨海默病、肥胖症等）
    • 最終用戶（生物技術/製藥公司、學術/研究機構等）
    • 按國家
  • MEA：國家分析
    • 南非基因工程工具
    • 沙特阿拉伯基因工程工具
    • 阿聯酋基因工程工具
    • 以色列基因工程工具

第 11 章市場動態

  • 司機
  • 做

第12章市場趨勢與發展

  • 近期發展狀況
  • 併購
  • 產品發布

第 13 章基因工程工具的全球市場：SWOT 分析

第 14 章波特的五力分析

  • 行業競爭
  • 新進入的可能性
  • 供應商的力量
  • 客戶力量
  • 替代品的威脅

第15章競爭格局

  • Business Overview
  • Product Offerings
  • Recent Developments
  • Financials（As Reported）
  • Key Personnel
  • SWOT Analysis
    • Thermo Fisher Scientific Inc
    • CRISPR Therapeutics AG
    • Editas Medicine, Inc.
    • Intellia Therapeutics, Inc
    • Merck KGaA
    • Horizon Discovery Ltd
    • GeneCopoeia Inc
    • Takara Bio Inc
    • Sangamo Therapeutics, Inc.
    • Genscript Biotech Corporation

第16章 戰略建議

簡介目錄
Product Code: 8085

Global genetic engineering tool market is expected to show robust growth in the forecast years 2024-2028. This can be ascribed to the increasing advancements in the field of biotechnology and genetics. The growing popularity of genomic medicine and personalized medicine is driving the growth of the global genetic engineering tool market in the coming years. As of 2020, the number of personalized medicine available in the United States was around 286.

The process of using recombinant Deoxyribonucleic Acid (rDNA) technology to create alterations in the genetic map of an organism is categorized as genetic engineering. These altercations are done through various biotechnological processes like insertion, deletion, CRISPR, etc. These techniques are termed genetic engineering tools. Genetic modifications have various purposes like pharmaceutical production, protein enhancement, genetic studies, etc., and thus genetic engineering tools are rapidly being introduced, and consistent research is being carried out.

Pharmaceutical Industry Growth Drives Market Growth

The Healthcare industry is rapidly expanding globally, and increasing financial aid for the development of the healthcare industry is further creating lucrative opportunities for the growth of market growth. One of the sectors, the pharmaceutical sector, is most advancing and registers phenomenal growth in the coming years due to the extended utilization of genetic engineering tools in their production, design, and manufacturing. The rapid growth of precision medicine, genomic medicine, and other advanced methods of therapeutics is further aiding the growth of the global genetic engineering tools market in the upcoming five years.

The first-ever successful product of genetic engineering in the pharmaceutical industry was protein drugs like insulin. Micro-organisms used as bioreactors were utilized to multiply the quantity of the protein and thus mass-produced the drug. Transgenic animals and transgenic plants are also utilized for the production of various protein drugs that are not possible to be produced in the micro-organisms.

Research & Technology Development Support Market Growth

Genetic engineering is a consistently developing sector of biotechnology. With prolonging and continuous research going on related to gene editing and genome manipulating studies, the global genetic engineering tool market is bound to register robust growth in the coming years. With the prevalence of chronic diseases and the surging demand for therapeutic approaches toward those diseases, the global genetic engineering tool market is supporting growth in the forecast period.

Minichromosomal technology and RNA transcription alterations are some of the major genetic engineering tools expecting more research, thereby supporting the growth of the global genetic engineering tools market in the coming years. CRISPR-Cas9 gene altercations is a gene therapy that is expected to aid market growth. Moreover, genetic engineering has various applications. Further applications of genetic engineering tools in genome modification are another prospective research segment that would drive the growth of the Global Genetic Engineering Tools market in the forecast years.

Genetic Engineering in Agriculture

Demands for advancement in the agriculture sector with the help of genetic engineering are further substantiating the growth of the global genetic engineering tool market in the coming years. According to the biotech lobbying group ISAAA, GM crops covered 191.7 million hectares in 2018, an increase of 1% from 2017. With 75 million hectares (39% of the world's area), the United States is the world's largest producer of GM crops. Increased crop yields, reduced costs for food or drug production, reduced need for pesticides, enhanced nutrient composition, and food quality, resistance to pests and disease, greater food security, and medical benefits to the world's growing population are some of the major advantages that involve the use of genetic engineering tools. The involvement of genetic engineering tools in agriculture to produce better crops will also drive the growth of the Global Genetic Engineering Tool market in the coming years.

Market Segmentation

Global genetic engineering tool market is segmented based on type, therapeutic area, end-user, and region. Based on type, the market is further fragmented into genome-scale editing tools and genome-scale engineering tools. Based on therapeutic areas, the market is bifurcated into sickle cell disease, heart disease, diabetes, Alzheimer's disease, obesity, and others. Based on end-user, the market is again sub-segmented into biotechnology & pharmaceutical companies, academic & research institutions, and others. The market analysis also studies the regional segmentation to devise regional market segmentation, divided among Asia-Pacific region, North American region, European region, South American region, and the Middle East & African region.

Company Profiles

Thermo Fisher Scientific Inc, CRISPR Therapeutics AG, Editas Medicine, Inc., Intellia Therapeutics, Inc, Merck KGaA, Horizon Discovery Ltd, GeneCopoeia Inc, Takara Bio Inc., Sangamo Therapeutics, Inc., Genscript Biotech Corporation, are among the major market players in the global platform that lead the market growth of the global genetic engineering tool market.

Report Scope:

In this report, global genetic engineering tool market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genetic Engineering Tool Market, By Type:

  • Genome-Scale Editing Tools
    • CRISPR
    • MAGE
    • CRMAGE
    • CREATE
    • Others
  • Genome-Scale Engineering Tools
    • Promoter Engineering
    • Ribosomal Binding Site (RBS) Engineering
    • Synthetic Small Regulatory RNA
    • Others
    • Genetic Engineering Tool Market, By Therapeutic Area:
  • Sickle Cell Disease
  • Heart Disease
  • Diabetes
  • Alzheimer's Disease
  • Obesity
  • Others

Genetic Engineering Tool Market, By End User:

  • Biotechnology & Pharmaceutical Companies
  • Academic & Research Institutions
  • Others

Genetic Engineering Tool Market, By Region:

  • North America
    • United States
    • Mexico
    • Canada
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Thailand
    • Singapore
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Israel
  • South America
    • Brazil
    • Argentina
    • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global genetic engineering tool market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

  • 4.1. Commonly Used Genetic Engineering Techniques
  • 4.2. Commonly Used Gene Editing Techniques
  • 4.3. Benefits of Using Genetic Engineering Tools
  • 4.4. Preference for Genetic Engineering Tools, By Therapeutic Area
  • 4.5. Barriers to Adoption of Genetic Engineering Tools
  • 4.6. Brand Awareness

5. Global Genetic Engineering Tools Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Genome Scale Editing Tools v/s Genome Scale Engineering Tools)
      • 5.2.1.1. Genome Scale Editing Tools (CRISPR, MAGE, CRMAGE, CREATE, Others)
      • 5.2.1.2. Genome Scale Engineering Tools (Promoter Engineering, Ribosomal Binding Site (RBS) Engineering, Synthetic Small Regulatory RNA, Others)
    • 5.2.2. By Therapeutic Area (Sickle Cell Disease, Heart Disease, Diabetes, Alzheimer's Disease, Obesity, Others)
    • 5.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
    • 5.2.4. By Company (2022)
    • 5.2.5. By Region
  • 5.3. Market Map
    • 5.3.1. By Type
    • 5.3.2. By Therapeutic Area
    • 5.3.3. By End User
    • 5.3.4. By Region

6. North America Genetic Engineering Tools Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type (Genome Scale Editing Tools v/s Genome Scale Engineering Tools)
      • 6.2.1.1. Genome Scale Editing Tools (CRISPR, MAGE, CRMAGE, CREATE, Others)
      • 6.2.1.2. Genome Scale Engineering Tools (Promoter Engineering, Ribosomal Binding Site (RBS) Engineering, Synthetic Small Regulatory RNA, Others)
    • 6.2.2. By Therapeutic Area (Sickle Cell Disease, Heart Disease, Diabetes, Alzheimer's Disease, Obesity, Others)
    • 6.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Genetic Engineering Tools Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Therapeutic Area
        • 6.3.1.2.3. By End User
    • 6.3.2. Mexico Genetic Engineering Tools Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Therapeutic Area
        • 6.3.2.2.3. By End User
    • 6.3.3. Canada Genetic Engineering Tools Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Therapeutic Area
        • 6.3.3.2.3. By End User

7. Europe Genetic Engineering Tools Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type (Genome Scale Editing Tools v/s Genome Scale Engineering Tools)
      • 7.2.1.1. Genome Scale Editing Tools (CRISPR, MAGE, CRMAGE, CREATE, Others)
      • 7.2.1.2. Genome Scale Engineering Tools (Promoter Engineering, Ribosomal Binding Site (RBS) Engineering, Synthetic Small Regulatory RNA, Others)
    • 7.2.2. By Therapeutic Area (Sickle Cell Disease, Heart Disease, Diabetes, Alzheimer's Disease, Obesity, Others)
    • 7.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Genetic Engineering Tools Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Therapeutic Area
        • 7.3.1.2.3. By End User
    • 7.3.2. Germany Genetic Engineering Tools Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Therapeutic Area
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Genetic Engineering Tools Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Therapeutic Area
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Genetic Engineering Tools Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Therapeutic Area
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Genetic Engineering Tools Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Therapeutic Area
        • 7.3.5.2.3. By End User

8. Asia-Pacific Genetic Engineering Tools Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type (Genome Scale Editing Tools v/s Genome Scale Engineering Tools)
      • 8.2.1.1. Genome Scale Editing Tools (CRISPR, MAGE, CRMAGE, CREATE, Others)
      • 8.2.1.2. Genome Scale Engineering Tools (Promoter Engineering, Ribosomal Binding Site (RBS) Engineering, Synthetic Small Regulatory RNA, Others)
    • 8.2.2. By Therapeutic Area (Sickle Cell Disease, Heart Disease, Diabetes, Alzheimer's Disease, Obesity, Others)
    • 8.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Genetic Engineering Tools Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Therapeutic Area
        • 8.3.1.2.3. By End User
    • 8.3.2. India Genetic Engineering Tools Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Therapeutic Area
        • 8.3.2.2.3. By End User
    • 8.3.3. South Korea Genetic Engineering Tools Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Therapeutic Area
        • 8.3.3.2.3. By End User
    • 8.3.4. Japan Genetic Engineering Tools Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Therapeutic Area
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Genetic Engineering Tools Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Therapeutic Area
        • 8.3.5.2.3. By End User
    • 8.3.6. Thailand Genetic Engineering Tools Market Outlook
      • 8.3.6.1. Market Size & Forecast
        • 8.3.6.1.1. By Value
      • 8.3.6.2. Market Share & Forecast
        • 8.3.6.2.1. By Type
        • 8.3.6.2.2. By Therapeutic Area
        • 8.3.6.2.3. By End User
    • 8.3.7. Singapore Genetic Engineering Tools Market Outlook
      • 8.3.7.1. Market Size & Forecast
        • 8.3.7.1.1. By Value
      • 8.3.7.2. Market Share & Forecast
        • 8.3.7.2.1. By Type
        • 8.3.7.2.2. By Therapeutic Area
        • 8.3.7.2.3. By End User

9. South America Genetic Engineering Tools Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type (Genome Scale Editing Tools v/s Genome Scale Engineering Tools)
      • 9.2.1.1. Genome Scale Editing Tools (CRISPR, MAGE, CRMAGE, CREATE, Others)
      • 9.2.1.2. Genome Scale Engineering Tools (Promoter Engineering, Ribosomal Binding Site (RBS) Engineering, Synthetic Small Regulatory RNA, Others)
    • 9.2.2. By Therapeutic Area (Sickle Cell Disease, Heart Disease, Diabetes, Alzheimer's Disease, Obesity, Others)
    • 9.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Genetic Engineering Tools Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Therapeutic Area
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Genetic Engineering Tools Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Therapeutic Area
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Genetic Engineering Tools Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Therapeutic Area
        • 9.3.3.2.3. By End User

10. Middle East and Africa Genetic Engineering Tools Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type (Genome Scale Editing Tools v/s Genome Scale Engineering Tools)
      • 10.2.1.1. Genome Scale Editing Tools (CRISPR, MAGE, CRMAGE, CREATE, Others)
      • 10.2.1.2. Genome Scale Engineering Tools (Promoter Engineering, Ribosomal Binding Site (RBS) Engineering, Synthetic Small Regulatory RNA, Others)
    • 10.2.2. By Therapeutic Area (Sickle Cell Disease, Heart Disease, Diabetes, Alzheimer's Disease, Obesity, Others)
    • 10.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Genetic Engineering Tools Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Therapeutic Area
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Genetic Engineering Tools Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Therapeutic Area
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Genetic Engineering Tools Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Therapeutic Area
        • 10.3.3.2.3. By End User
    • 10.3.4. Israel Genetic Engineering Tools Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Type
        • 10.3.4.2.2. By Therapeutic Area
        • 10.3.4.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Genetic Engineering Tool Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Product Offerings
  • 15.3. Recent Developments
  • 15.4. Financials (As Reported)
  • 15.5. Key Personnel
  • 15.6. SWOT Analysis
    • 15.6.1. Thermo Fisher Scientific Inc
    • 15.6.2. CRISPR Therapeutics AG
    • 15.6.3. Editas Medicine, Inc.
    • 15.6.4. Intellia Therapeutics, Inc
    • 15.6.5. Merck KGaA
    • 15.6.6. Horizon Discovery Ltd
    • 15.6.7. GeneCopoeia Inc
    • 15.6.8. Takara Bio Inc
    • 15.6.9. Sangamo Therapeutics, Inc.
    • 15.6.10. Genscript Biotech Corporation

16. Strategic Recommendations